Clinical trial
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women…
NCT00038103 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00038103 |
|---|---|
| Title | Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen |
| Official title | Open-Label, Multicentre, Controlled Study Of Exemestane (Aromasin®) With Or Without Celecoxib (Celebrex®) In Postmenopausal Women With Advanced Breast Cancer (ABC) Having Progressed On Tamoxifen |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Exemestane, Celecoxib + Exemestane |
| Enrollment | 111 |
| Start date | Jan 1, 2002 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | May 30, 2002 |
| Last update posted | Feb 25, 2010 |
| Countries | Belgium, Brazil, Canada, Colombia, India, Mexico, Peru, Philippines, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: